Trevena Inc. (TRVN)
1.71
-0.08 (-4.47%)
At close: Jan 15, 2025, 3:14 PM
undefined% (undefined)
| Bid | 2.39 |
| Market Cap | 1.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -48.89 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.5 |
| Volume | 100 |
| Avg. Volume (20D) | 5,873 |
| Open | 1.71 |
| Previous Close | 1.79 |
| Day's Range | 1.71 - 1.71 |
| 52-Week Range | 1.13 - 18.55 |
| Beta | undefined |
About TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abno...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 23
Stock Exchange NASDAQ
Ticker Symbol TRVN
Website https://www.trevena.com
Analyst Forecast
According to 1 analyst ratings, the average rating for TRVN stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 192.40% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
3 months ago ·
Source
-45.77%
Trevena shares are trading lower after the company...
Unlock content with
Pro Subscription
3 months ago ·
Source
+15.25%
Trevena shares are trading lower after the company announced it received a Nasdaq delisting notification.
